Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus - Trial NCT06236256
Access comprehensive clinical trial information for NCT06236256 through Pure Global AI's free database. This phase not specified trial is sponsored by Sheba Medical Center and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system
Interventional
device
Sponsor & Location
Sheba Medical Center
Timeline & Enrollment
N/A
Jan 09, 2024
Sep 15, 2025
Primary Outcome
Improvement of glucose measures in older individuals
Summary
The trial is a randomized controlled, parallel group design study. Patients will be followed
 up during approximatively 12 months.
 
 Patients will be randomized to either the MDI/CSII group which will continue their treatment
 as per routine procedures and the advanced Hybrid Closed Loop system (AHCL) group which will
 be connected to the Minimed 780G system. .
 
 At the end of the 12 month study period, we will evaluate whether the AHCL system improved
 glucose indices in older individuals with Type 1 diabetes mellitus (T1DM) and assess whether
 the ACHL treatment improved physical capacity, frailty & sarcopenia indices as well as
 quality of life and cognitive functions.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06236256
Device Trial